(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANTICORPOS SPIKE(S) ANTI-SARS-CoV-2 E SEU USO NO TRATAMENTO DE COVID-19

Em AnáliseInvention PatentPCT · US2022082331

Application data

Invention Patent ANTICORPOS SPIKE(S) ANTI-SARS-CoV-2 E SEU USO NO TRATAMENTO DE COVID-19 de NOVAVAX, INC. — IPC A61K 38/08
Invention Patent ANTICORPOS SPIKE(S) ANTI-SARS-CoV-2 E SEU USO NO TRATAMENTO DE COVID-19 de NOVAVAX, INC. — IPC A61K 38/08. Drawing published by the INPI in the Industrial Property Gazette.

Number

112024012645

Type

Invention Patent

Filing

12/23/2022

Publication

09/17/2024

PCT

US2022082331

Progress at the INPI

  1. Filing12/23/22
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 12/23/2022. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 09/17/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

NOVAVAX, INC.

US

See this company's full portfolio

Inventors

G. S. (pessoa física)

US

N. P. (pessoa física)

US

Technical data

Priority claims

US

63/293,451 · 12/23/2021

Abstract

ANTICORPOS SPIKE(S) ANTI-SARS-CoV-2 E SEU USO NO TRATAMENTO DE COVID-19. A presente invenção fornece anticorpos que se ligam à proteína Spike (S) do SARS-CoV-2. A invenção refere-se adicionalmente a composições farmacêuticas, composições imunoterapêuticas e métodos que usam os anticorpos acima mencionados que se ligam à proteína Spike (S) do SARS-CoV- 2.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

09/17/2024

RPI 2802

Alteração de dados cadastrais

#1.1

07/02/2024

RPI 2791

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.